Central nervous system toxicity of high-dose cytosine arabinoside.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D002526:Cerebellar Diseases / Q000139:chemically induced / Q000473:pathology; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009759:Nystagmus, Pathologic / Q000139:chemically induced; D013577:Syndrome; D014202:Tremor / Q000139:chemically induced
D003561:Cytarabine